StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)

Investment analysts at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note issued to investors on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Vanda Pharmaceuticals in a report on Monday.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA opened at $4.81 on Friday. Vanda Pharmaceuticals has a 52-week low of $3.46 and a 52-week high of $6.75. The business has a fifty day moving average of $4.86 and a two-hundred day moving average of $5.20. The stock has a market cap of $280.46 million, a PE ratio of -17.18 and a beta of 0.76.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now directly owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. bought a new stake in Vanda Pharmaceuticals during the 2nd quarter worth about $39,000. ORG Wealth Partners LLC acquired a new position in Vanda Pharmaceuticals in the third quarter valued at approximately $40,000. China Universal Asset Management Co. Ltd. boosted its stake in Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 4,374 shares during the last quarter. XTX Topco Ltd bought a new position in Vanda Pharmaceuticals in the second quarter valued at approximately $75,000. Finally, Intech Investment Management LLC acquired a new stake in Vanda Pharmaceuticals during the 3rd quarter worth $84,000. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.